Literature DB >> 11528480

Virus-mediated killing of cells that lack p53 activity.

K Raj1, P Ogston, P Beard.   

Abstract

A major goal of molecular oncology is to identify means to kill cells lacking p53 function. Most current cancer therapy is based on damaging cellular DNA by irradiation or chemicals. Recent reports support the notion that, in the event of DNA damage, the p53 tumour-suppressor protein is able to prevent cell death by sustaining an arrest of the cell cycle at the G2 phase. We report here that adeno-associated virus (AAV) selectively induces apoptosis in cells that lack active p53. Cells with intact p53 activity are not killed but undergo arrest in the G2 phase of the cell cycle. This arrest is characterized by an increase in p53 activity and p21 levels and by the targeted destruction of CDC25C. Neither cell killing nor arrest depends upon AAV-encoded proteins. Rather, AAV DNA, which is single-stranded with hairpin structures at both ends, elicits in cells a DNA damage response that, in the absence of active p53, leads to cell death. AAV inhibits tumour growth in mice. Thus viruses can be used to deliver DNA of unusual structure into cells to trigger a DNA damage response without damaging cellular DNA and to selectively eliminate those cells lacking p53 activity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11528480     DOI: 10.1038/35091082

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  68 in total

1.  Enhanced long-term transduction and multilineage engraftment of human hematopoietic stem cells transduced with tyrosine-modified recombinant adeno-associated virus serotype 2.

Authors:  M Ariel Kauss; Laura J Smith; Li Zhong; Arun Srivastava; K K Wong; Saswati Chatterjee
Journal:  Hum Gene Ther       Date:  2010-09       Impact factor: 5.695

2.  Adeno-Associated Virus Type 2 and Hepatocellular Carcinoma?

Authors:  Kenneth I Berns; Barry J Byrne; Terence R Flotte; Guangping Gao; William W Hauswirth; Roland W Herzog; Nicholas Muzyczka; Thierry VandenDriessche; Xiao Xiao; Sergei Zolotukhin; Arun Srivastava
Journal:  Hum Gene Ther       Date:  2015-12       Impact factor: 5.695

Review 3.  Adeno-associated Virus as a Mammalian DNA Vector.

Authors:  Max Salganik; Matthew L Hirsch; Richard Jude Samulski
Journal:  Microbiol Spectr       Date:  2015-08

4.  How adeno-associated virus Rep78 protein arrests cells completely in S phase.

Authors:  Carole Berthet; Kenneth Raj; Philippe Saudan; Peter Beard
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-12       Impact factor: 11.205

5.  Bocavirus infection induces mitochondrion-mediated apoptosis and cell cycle arrest at G2/M phase.

Authors:  Aaron Yun Chen; Yong Luo; Fang Cheng; Yuning Sun; Jianming Qiu
Journal:  J Virol       Date:  2010-03-24       Impact factor: 5.103

6.  ICP0 gene expression is a herpes simplex virus type 1 apoptotic trigger.

Authors:  Christine M Sanfilippo; John A Blaho
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

Review 7.  Gene therapy for hemophilia: what does the future hold?

Authors:  Bhavya S Doshi; Valder R Arruda
Journal:  Ther Adv Hematol       Date:  2018-08-27

8.  Bocavirus infection induces a DNA damage response that facilitates viral DNA replication and mediates cell death.

Authors:  Yong Luo; Aaron Yun Chen; Jianming Qiu
Journal:  J Virol       Date:  2010-11-03       Impact factor: 5.103

9.  Adeno-associated virus type 2 modulates the host DNA damage response induced by herpes simplex virus 1 during coinfection.

Authors:  Rebecca Vogel; Michael Seyffert; Regina Strasser; Anna P de Oliveira; Christiane Dresch; Daniel L Glauser; Nelly Jolinon; Anna Salvetti; Matthew D Weitzman; Mathias Ackermann; Cornel Fraefel
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

10.  Down-regulation of p53 by double-stranded RNA modulates the antiviral response.

Authors:  Joao T Marques; Dominique Rebouillat; Chilakamarti V Ramana; Junko Murakami; Jason E Hill; Andrei Gudkov; Robert H Silverman; George R Stark; Bryan R G Williams
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.